{"entity":{"id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Tislelizumab and Docetaxel in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07669415 by LaNova Medicines Limited, with 108 participants planned, started 2026-07-29 and due to reach its primary completion in 2027-12-15. Interventions recorded: LM-168, Tislelizumab and Docetaxel injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07669415","url":"https://clinicaltrials.gov/study/NCT07669415"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab","docetaxel"],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07669415","phase":"2","setting":"A Phase II，Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials","sponsor":"LaNova Medicines Limited","enrolled":108,"outcomes":[]},"route":"/trials/nct07669415/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}